Kuvandudza Kwakakosha muChirwere Kuoma kweAtopic Dermatitis

Pamasvondo gumi nematanhatu, 16 muzana yevarwere vane mwero-kusvika-yakanyanya atopic dermatitis (AD) vachigamuchira lebrikizumab yakasanganiswa neyakajairwa-ye-kutarisira topical corticosteroids (TCS) vakawana inosvika makumi manomwe neshanu muzana ekuvandudza mukuoma kwechirwere (EASI-70 *) mu iyo ADhere kutongwa, Eli Lilly uye Kambani (NYSE: LLY) yakaziviswa nhasi ku75th Year Revolutionizing Atopic Dermatitis (RAD) Musangano. Lebrikizumab, inoongorora IL-75 inhibitor, yakaratidzawo kuvandudzwa kwe itch, kukanganisa kurara, uye hupenyu hwehupenyu kana hwakasanganiswa neTCS, zvichienzaniswa ne placebo pamwe neTCS.

"Data yanhasi yeADhere, pamwe nemhedzisiro kubva kuzvidzidzo zveAdvocate monotherapy, zvinoratidza mukana welebrikizumab kuderedza mutoro wechirwere uye kupa zororo kuvanhu vane atopic dermatitis isingadzoreki kana vakashandiswa vari voga kana kusanganiswa nemusoro," akadaro Eric Simpson, MD, MCR. Purofesa weDermatology uye Director weClinical Research kuOregon Health & Science University muPortland, uye mukuru anoongorora weADhere. "Lebrikizumab yakanangana neiyo IL-13 nzira, iyo inoita basa repakati muchirwere ichi chisingaperi chekuzvimba. Mhedzisiro iyi inosimbisa kunzwisisa kwedu lebrikizumab mune atopic dermatitis uye inobatsira kuimisa senzira nyowani yekurapa.

Lebrikizumab ibhuku, monoclonal antibody (mAb) inosungira kune interleukin 13 (IL-13) protein ine high affinity kudzivirira zvakananga kuumbwa kweIL-13Rα1 / IL-4Rα (Type 2 receptor) iyo inovhara kudzika kwemvura kuburikidza neIL. -13 pathway.1-5 IL-13 inobata basa guru muRudzi rwechipiri kuzvimba muna AD.2 Muna AD, IL-6,7 inodzika zviratidzo nezviratidzo zvinosanganisira kusashanda kweganda barriers, itch, utachiona uye yakaoma, yakakora nzvimbo dzeganda. .13

Pakati pevarwere vanotora lebrikizumab pamwe neTCS, 41 muzana vakawana ganda rakajeka kana rakajeka (IGA) pamavhiki e16 zvichienzaniswa ne22 muzana yevarwere vanotora placebo pamwe neTCS. Pamasvondo gumi nematanhatu, makumi manomwe muzana evarwere vanotora lebrikizumab pamwe neTCS vakawana mhinduro yeEASI-16 zvichienzaniswa ne70 muzana yekutora placebo pamwe neTCS. Kusiyana pakati pevarwere vanogamuchira lebrikizumab pamwe chete neTCS uye placebo neTCS yakaonekwa kutanga kwemavhiki mana eEASI-75.

Varwere vakabatwa nelebrikizumab pamwe neTCS vakawanawo kuvandudzwa kwakakosha pamagumo ekupedzisira anosanganisira kucheneswa kweganda uye kurumwa, kukanganiswa kweiyo itch pakurara, uye hutano hwehupenyu, zvichienzaniswa ne placebo neTCS. Misiyano ine musoro yekiriniki yakaonekwa sekutanga kwemavhiki mana nekuda kwekufunuka, kukanganiswa kweiyo itch pakurara, uye mhando yehupenyu matanho.

Mhedzisiro dzekuchengetedza dzaienderana neyekutanga lebrikizumab zvidzidzo muAD. Varwere vanotora lebrikizumab pamwe neTCS, vachienzaniswa ne placebo pamwe neTCS, vakashuma kuwanda kwepamusoro kwezviitiko zvakashata (lebrikizumab pamwe neTCS: 43%, placebo pamwe neTCS: 35%). Zviitiko zvakawanda zvakashata zvaive zvinyoro kana zvine mwero mukuomarara uye zvisina musoro uye hazvina kutungamira mukuregedzwa kwekurapa. Zviitiko zvakajairika zvakanyanya kune avo vari palebrikizumab vaive conjunctivitis (5%) uye musoro (5%).

"Lilly ari kushanda kupa simba kuvanhu vane zvirwere zvine chekuita neganda, senge atopic dermatitis, kuti vararame hupenyu hwavo zvizere," akadaro Lotus Mallbris, MD, Ph.D., mutevedzeri wemutungamiri weglobal immunology development and medical affairs kuLilly. . "Tinoziva kukosha kwakakosha kune dzimwe sarudzo kune vanhu vane chirwere chisingagone kudzorwa nemusoro. Tinotarisira kuona mhedzisiro izere kubva kuchirongwa chedu chakafara cheChikamu 3 uye kufambira mberi kwelebrikizumab pasi rese. "

Lilly achangobva kuzivisa 16-vhiki data kubva kuzvidzidzo zveAdvocate zvinoenderera mberi, uye mharidzo yakasimbiswa yemigumisiro yakaratidzwa paRAD 2022. Uyezve, data yenguva refu kubva kune zvidzidzo zveAdvocate ichabudiswa mumwedzi iri kuuya.

“Iyi mhedzisiro idanho rekuwedzera mukuzvipira kwedu kuendesa mishonga yemhando yepamusoro inoita mutsauko unoreva kuvarwere. Tinotarisira kuzivisa zviitiko zvitsva zvinonakidza mumwedzi iri kuuya,” akadaro Karl Ziegelbauer, Ph.D., Mukuru weSainzi weAlmirall SA.

Lilly ane kodzero dzakakwana dzekusimudzira uye kutengeserana kwelebrikizumab muUnited States nepasirese kunze kweEurope. Almirall yakapa mvumo yekugadzira nekutengesa lebrikizumab yekurapa kwedermatology zviratidzo, kusanganisira AD, muEurope.